Platelet-rich growth factor in oral and maxillofacial surgery

Uma Shanker Pal, Shadab Mohammad, Rakesh K. Singh, Somdipto Das, Nimisha Singh, Mayank Singh

ABSTRACT

Platelet-rich growth factor is an innovative regenerative therapy used to promote hard and soft tissue healing. It involves the application of autologous platelet-leukocyte-rich plasma containing growth factors and thrombin directly to the site of treatment. It is the intrinsic growth factors released by activated platelets which are concentrated in a topical gel formula. Clinically, it is an affordable treatment with potentially broad spectrum of applications in maxillofacial surgery especially in the treatment of complex or refractory wounds. The present article reviews its various applications not only in the specialization of oral and maxillofacial surgery but also in regenerative medicine.

Key words: Alveolar clefts, bisphosphonate related osteonecrosis of the jaw, bone healing, nerve regeneration, platelet rich growth factors

INTRODUCTION

Platelet-rich growth factor (PRGF) is a boon in recent years in the field of regenerative medicine and also gaining attention of various scientists in the field of regenerative medicine. The inherent property of PRGF mainly to promote soft and hard tissues has its application in the various fields of medicine and surgery including oral and maxillofacial surgery.

Human body’s relatively poor capability to auto regenerate increases the demands for tissues and organs. Neither is there an abundance of organ donors in our society nor the actual replication of lost tissues possible by transplantation, which prompted the field of regenerative medicine as the subject of interest among the various research workers.

PRGF is also a less invasive procedure and reduces donor-site morbidity. In the presence of body’s proteins and polypeptides responsible for cellular communication and naturally available scaffold in the form of three dimensional fibrin network, PRGF is a promising way of utilization of body’s natural reservoir in the field of regenerative medicine.

This review is a sincere effort to accumulate the literature of the various applications of PRGF in oral and maxillofacial surgery into a comprehensive one.

Platelet-rich growth factor
PRGF contains platelets in the pool of plasma. The optimal platelet count in PRGF is a poorly defined subject in the literature. Whitman et al.\(^1\) stated that the platelet count in PRGF should oscillate between 500,000 and 1,000,000 cells/L. In the initial work of Marx et al.\(^2\) the mean platelet count achieved was 785,000 cells/L using the same protocol as Whitman et al.\(^2\) Landesberg et al.\(^3\) evaluating different centrifugation speeds, determined the best protocol to be the one that provided a platelet count of 935,000 cells/L. At this stage of knowledge about this autogenous growth factor concentration, several studies have shown that a platelet count between 500,000 and 1,000,000 cells/L is considered optimal.\(^4\)\(^-\)\(^6\)

The first attempt to standardize a platelet concentration
for platelet rich growth factor (PRGF) was proposed by Marx. The author argued that the best biological response occurs when a 4-5 fold increase over the baseline platelet number is achieved. Hence, the ideal PRP should present a platelet count of over 1 million cells/L.\(^2\)

Platelets are considered living depots of enormous growth factors which once activated after centrifugation by calcium chloride or autologous thrombin, release biologically active proteins which help in tissue mitogenesis, differentiation, and morphogenesis.

The proteins derived from platelets include platelet-derived growth factor (PDGF), transforming growth factor (TGF-\(\beta\)), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). Plasma contains certain natural growth factors in the name of insulin-like growth factor (IGF) and hepatocyte growth factor (HGF).

Some of the main roles of these enumerated growth factors are given below:

**PDGF:** A glycoprotein, PDGF has a molecular weight of approximately 30 kd. PDGF is a family of five homo- and heterodimers (\(\alpha\alpha, \alpha\beta, \beta\beta, \gamma\gamma, \text{and } \delta\delta\) isomers) of disulfide-bonded polypeptides encoded by four genes (\(\alpha, \beta, \gamma, \delta\)), which bind to two different receptor tyrosine kinases (PDGF receptors \(\alpha\) and \(\beta\)) at the cell surface.\(^7\) PDGF-C (2000)\(^8\) and PDGF-D (2001)\(^9\) were recently discovered in comparison to PDGF-\(\alpha\) and PDGF-\(\beta\).

PDGF-\(\alpha\beta\) and PDGF-\(\beta\beta\) are seen to have strong mitogenic effects on stem cells and osteoblasts and promote angiogenesis and collagen synthesis, thus enhancing the process of wound healing. PDGF \(\alpha\beta\) and \(\beta\beta\) are secreted by platelets at the injury site, whereas \(\alpha\alpha\) isofrom is secreted by unstimulated osteoblasts cell lineages.\(^10,11\)

During early wound repair (proliferative phase), PDGF leads to proliferation of fibroblasts which synthesize provisional matrix composed of glycosaminoglycans and fibronectin.\(^12\) PDGF-\(\alpha\beta\) and PDGF-\(\beta\beta\), but not PDGF-\(\alpha\alpha\), promote contraction of collagen matrices\(^13\) and mediate the fibroblast-dependent secretion of collagenases, which is important in the late stage of wound healing (remodeling phase).\(^14\)

**TGF:** TGFs are proteins of molecular weight of approximately 25 kd. TGF-\(\beta\) exists in three isoforms, namely TGF-\(\beta1\), TGF-\(\beta2\), and TGF-\(\beta3\). TGF-\(\beta\) family belongs to a superfamily of proteins that includes inhibin, activin, antimullerian hormone, bone morphogenetic protein, decapentaplegic, and Vg1.\(^15\)

TGF-\(\beta1\) is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. The TGF-\(\beta\) receptor is a serine/threonine kinase which controls the production of the extracellular matrix. Its topical application leads to an enhanced production of collagen and fibronectin.\(^16\) It has also been shown that TGF-\(\beta\) stimulates mesenchymal precursor cells in the periosteum to proliferate and differentiate.\(^17\)

**VEGF:** It induces both chemotaxis and endothelial differentiation thus leading to angiogenesis.\(^18\) It is mitogenic and promotes the chemotaxis and differentiation of epithelial, renal, and glial cells as well as fibroblasts.

**EGF:** It has both chemotactic and mitogenic effects on epithelial cells and fibroblasts. It is a potent stimulator for granulation tissue formation. Fibroblasts, preosteoblasts and prechondrocytes have a high number of receptor for EGF.\(^19\)

**IGF:** The IGFs are polypeptides which have a large sequence homology to insulin.\(^20\) This group of proteins, also called the IGF-axis, consists of two types of membrane receptors: IGF receptors I and II (IGFR-I and II), two ligands (IGF-I and II), a group of six IGF-binding proteins (IGF BP-1 to 6), and a few IGFBP-associated proteases.\(^21\) IGF-II seems to play an important role in early cell development,\(^22\) whereas IGF-I is relevant at a later point of time in maximizing growth. Although IGF-II is the most abundant growth hormone in bone, IGF-I was found to be more potent.\(^23\) Furthermore, IGFS stimulate efficient reepithelization of wounds.\(^24\)

Studies have revealed the anti-inflammatory effect of plasma rich in growth factors which could be mediated by the inhibition of transactivation of transcription factor kappa B (NF-kB) and the expression of CO \(\times 2\) and CXCR 4 due to the high content of plasmatic HGF, IL-4 and tumor necrosis factor-alpha (TNF-\(\alpha\)).\(^25\)

**Clinical applications in oral and maxillofacial surgery**

The ability of PRGF in accelerating soft and hard tissue healing has stimulated the research of its clinical applications in various areas of oral and maxillofacial surgery, which includes healing of extraction sockets including impacted tooth, implantology, cleft lip and palate, ulcer management, and bisphosphonate-related osteonecrosis of the jaw (BRONJ).

**Platelet-rich growth factor and bone healing**

One of the initial studies of regenerative medicine in healing sockets was done by Anitua et al. in 1999.\(^26\)
The study consisted of 20 patients divided into both the study and the control groups. It was found that the bony and soft tissue healing was extensive with well-organized bony trabeculae in the study group. On the contrary, the control group showed only presence of connective tissue with little matured bone. This study also correlates well with the study by Célio-Marino et al. Fifteen patients with bilateral impacted molar were taken for study, and following extraction, one of the socket was treated with PRGF and the other by secondary healing. It was shown with the help of radiographic bone density measurements that bone formation was significantly faster compared with normal healing ($P < 0.01$). Although the difference is insignificant on the seventh day and sixth month, but bone formation was faster and better on first, second, and third months.

But Gürbüzer et al. found no significant differences between sockets healed with and without PRGF ($P > 0.05$) using bone scintigraphy. The author gave the reasoning that both the platelet counts and level of growth factors in PRP are dependent on preparation methods. Similarly, the effect of PRGF in wound healing is dose dependent. Gürbüzer stressed that highly concentrated platelet preparations (6-11 folds above normal range) could have an inhibitory effect on bone healing by stimulating osteoclastogenesis.

PRGF and implants including sinus lift
Another field where PRGF is used with excellent results is in the augmentation of maxillary sinus floor for implant placement. It is found that PRGF along with bone grafts not only facilitates manipulation and administration of the graft but the fibrin scaffold can also be used as an autologous sealant biomaterial in cases of Schneiderian membrane. Anitua et al. carried out a prospective study of 5 patients and concluded that not only PRGF facilitates bone augmentation but also reduces inflammation in the study group as compared with the control group. In this series, new vital bone in the study areas compared with the control was 21.4-8.4%. The number of blood vessels per mm$^2$ was also high in the study area ($116-7$). Similar positive results were also shown by Riaz et al. Pieri et al. conducted a study of mesenchymal stem cells, PRGF, and fluorohydroxyapatite with fluorohydroxyapatite alone. He concluded that after 12 weeks, there is a significant rise in sinus lift augmentation in the test site rather than the control site (42.51% vs. 18.98%; $P = 0.001$).

But Schaaf et al. radiographically compared the difference in sinus lift due to autogenous bone grafts and PRGF. The author conducted the study on 34 patients and the bone density was evaluated histomorphometrically and with help of computed tomography (CT) scan. Spearman correlation coefficient suggested no difference in bone density histomorphometrically and CT in therapy with PRP ($P = 0.55$; without PRP: $P = 0.80$). Similar results were also supported by the studies of Zhang et al. and Andreas Schlegel et al. on sinus floor elevation with bone substitutes and bone substitutes mixed with PRGF. Casati et al. conducted a study on mongrel dogs to study the effect of PRGF on bony dehiscences around peri-implant surfaces and found no significant differences in healing ($P > 0.05$). Hence, following review about PRGF application in bone healing, no significant results were found of its applications in sinus lift or bony dehiscence healing in terms of bone density or bone to implant contact.

PRGF and BRONJ
Patients who are on intravenous therapy of bisphosphonates are found to have higher incidence of aggressive and extensive BRONJ than patients with oral bisphosphonates. Conservative management of BRONJ especially grades II and III are found to be partly successful with resolution rate of 50% as compared with 80% with surgical management. The surgical management usually consists of wide resection of the bone till healthy bone is reached. Healthy bone is judged mainly by the color, fresh bleeding from the bone, though Pautke et al. developed a fluorescence-guided technique which consists of tetracycline uptake of healthy bone which delineates it from necrosed bone. Due to the paracrine effects on stimulated cells by the PRF, bone remodelling following surgical resection of BRONJ is mainly affected by bone remodelling associated with osteoclastic resorption and bone formation involving osteoblasts, osteoclasts, blood vessels, and perivascular stromal tissue.

In the study conducted by Curi et al. in 2011, 25 patients with BRONJ who failed to get treated conservatively were managed surgically with wide resection and application of PRGF. Twenty patients were found to have complete healing in a median follow-up period of 36 months. It was concluded from the study that treatment of refractory BRONJ with a combination of bone resection and PRP was found to be an effective therapy in most patients and should be considered an alternative treatment modality for management of advanced cases. Similar results of the efficacy of PRGF in bone regeneration and wound healing were also shown by Lee et al.

PRGF and alveolar clefts
Alveolar bone grafting has become an essential procedure in the treatment of cleft lip and palate. Both
autologous and xenografts are used for the regeneration of bone in the region of clefts. Among autografts, iliac crest is one of the good treatment options, as it is osteoconductive and the chances of rejection due to graft-versus-host response are not present. But in spite of these advantages none of the studies reported significant differences in bone density when either autografts or xenografts were used.

Oyama et al.\(^{[43]}\) conducted one of the initial studies of bone grafting with iliac crest cancellous bone with PRGF in 7 patients. The samples were divided into study and control groups, where PRP was mixed with bone grafts and only bone grafts used. Quantitative evaluation of the regenerated bone was made with three dimensional CT scans. The results were analysed as a ratio of volume of regenerated bone (VRB) to volume of alveolar cleft (VAC). It was found that in the study group, the minimum percentage of VRB/VAC was 71.27% (6 patients) and the maximum was 87.32% (2 patients) (average, 80.19% + 6.77% [SD]). In controls, the minimum percentage of VRB/VAC was 47.47% (9 patients) and the maximum was 77.97% (10 patients) (average, 63.67% + 13.94% [SD]).

Similar results were also concluded by Marukawa et al.\(^{[44]}\) and Behnia et al.\(^{[45]}\)

But Lee et al.\(^{[46]}\) conducted a longitudinal study to evaluate the outcomes of secondary autogenous bone grafts with PRP in alveolar clefts. It was found that no significant differences were observed in the bone resorption rate between the study group where PRP was added and the control group where it was not. Regarding prognostic factors, continuous mechanical stress affected bone resorption with or without PRP. The authors suggest that PRP may enhance bone remodeling in the early phase; however, PRP seems to be insufficient as a countermeasure against bone resorption following secondary bone graft in the long term.

**PRGF and nerve regeneration**

PRGF does not have its affect only in bony healing but also in soft tissue healing. It is also used in various applications in sports medicine such as tendonitis, Achilles tendon repair, tennis elbow, muscle injuries.\(^{[47]}\) It also found its applications in nerve regeneration, which can be both peripheral and central nervous system (CNS).

It is seen that most CNS diseases have a series of common pathological changes in the later period of diseases which induce apoptosis of neurons and glial cells. This aggravates neurological dysfunction in later life. Hence, its applications can be used as a novel therapeutic approach for CNS diseases, especially for traumatic brain or spinal cord injury, autoimmune diseases and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.

Although PRGF is not a neurotrophic factor, it does have a neuroprotective effect to promote adhesion and recovery of injured CNS. The various roles of PRGF suggested are as follows:

1. The cytokines in PRGF have protective actions on neurons from excitatory amino acid toxicity or nitric oxide toxicity of free radicals.\(^{[48,49]}\)
2. The trophic factors of PRGF have the potential in promoting axonal outgrowths and remyelination.\(^{[50-52]}\)
3. PRGF has been found to consist of certain proteins which even regulate neurotransmitter secretion.\(^{[53]}\)
4. The various growth factors in PRGF, such as PDGF, VEGF, TGF-β, facilitate angiogenesis and collagen formation.\(^{[54]}\)
5. The cytokines in PRGF have a role in activation of endogenous neural progenitor cells, and thus causing proliferation, migration, and differentiation to replace injured nerve cells.\(^{[55]}\)

Although there has been reported evidences in literature regarding the applications of PRGF in nerve regeneration and repair, but its role in humans is yet to be warranted.

**PRGF and hair transplantation**

PRGF is basically a protein molecule which has a role in angiogenesis after it interacts with cell-specific receptors, which stimulates healing and growth of new organic structures. Uebel, et al.\(^{[56]}\) conducted a study for the first time on the effects of PRGF in hair micrograft implant surgery. PRGF acts as a mediator to bring about togetherness among stem cells which are primitive ectodermal cells and dermal papilla derived from mesenchymal cells. Finally, this gives rise to the future follicular unit, which consists of the hair shaft, sebaceous glands, erectus pilus muscle, and the perifolliculum.

The author found a statistically significant difference observed in the yield of follicular units when comparing two groups: One in which PRGF added to the other where it was not ($P < 0.001$). The experimental group with the platelet plasma growth factor showed a density of 18.7 follicular units/cm², whereas the control group showed 16.7 follicular units/cm². The difference of 2.4 follicular units/cm² (95% confidence interval, 1.6-3.2 follicular units/cm²) represented a 15.1% increase in the yield of follicular unit density between the two
groups. Hence, the study proved the role of PRGF in treating baldness surgery.

**Conclusion**

Maxillofacial pathology where PRP is used includes fracture non-union, osteomyelitis, osteoradionecrosis, healing of extraction socket following removal of impacted molars, nerve regeneration, alveolar clefts, and also in cosmetic surgery including hair transplantation surgery. Our early experience in the use of PRP has found it to be a potentially effective clinical adjunct in the management of complex wounds and defects of both hard and soft tissues in the maxillofacial region with minimum morbidity of the donor.

This review is an effort to accumulate, among the innumerable data, certain applications of PRGF as reported in the literature. But none the less, we still recommend that extensive work in the field of regenerative medicine is still required to search for its other hidden effects.

**References**

1. Whitman DH, Berry RL, Green DM. Platelet gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997;55:1294-5.

2. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-46.

3. Landesberg R, Roy M, Glickman RS. Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 2000;58:297-300.

4. Lucarello E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AL, et al. Platelet-derived growth factors enhance proliferation of humanstromal stem cells. Biomaterials 2003;24:3095-100.

5. Aghalo TL, Mok PY, Freymiller EG. Investigation of platelet rich plasma in rabbit cranial defects: A pilot study. J Oral Maxillofac Surg 2002;60:1176-81.

6. Weibrich G, Kleis WK, Hafner G, Hitzler WE. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Cranio maxillofac Surg 2002;30:97-102.

7. Fredriksson L, Li H, Eriksson U. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15:197-204.

8. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-9.

9. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-6.

10. Canalis E, Varghese S, McCarthy TL, Centrella M. Role of platelet derived growth factor in bone cell function. Growth Regul 1992;2:151-5.

11. Rudyziel S, Shaikh S, Canalis E. Platelet-derived growth factor-AA and -BB (PDGF-AA and -BB) enhance the synthesis of PDGF-AA in bone cell cultures. Endocrinology 1994;134:2541-6.

12. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A. Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair. Am J Pathol 1992;140:1375-88.

13. Clark RA, Folkvord JM, Hart CE, Murray MJ, McPherson JM. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices. J Clin Invest 1989;84:1036-40.

14. Bauer EA, Cooper TW, Huang JS, Altman J, Deuel TF. Stimulation of in vitro human skin collagenase expression by platelet-derived growth factor. Proc Natl Acad Sci U S A 1985;82:4132-6.

15. Gassling VL, Ayl J, Springer IN, Hubert N, Willfang J. Platelet-rich plasma and platelet-rich fibrin in human cell culture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:48-55.

16. Lynch SE, Colvin RB, Antoniades NH. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989;84:640-6.

17. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990;110:2195-207.

18. Anitua E, Andia I, Ardanaz B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15.

19. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7.

20. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.

21. Holly J. Physiology of the IGF system. Novartis Found Symp 2004;262:19-26.

22. Morison IM, Becroft DM, Taniguchi T, Woods CG, Reeve AE. Somatic overgrowth associated with overexpression of insulin like growth factor II. Nat Med 1996;2:311-6.

23. Andrew JG, Hoyland J, Freemont AJ, Marsh D. Insulin like growth factor gene expression in human fracture callus. Calcif Tissue Int 1993;53:97-102.

24. Katz G, Lake M, Gidlund M. Insulin like growth factor-1 and -2 and their role in the re-epithelialisation of wounds; interactions with insulin like growth factor binding protein type 1. Scand J Plast Reconstr Surg Hand Surg 1994;28:107-12.

25. Alsberg E, Feinstein E, Joy MP, Prentiss M, Ingber DE. Magnetically-guided self-assembly of fibrin matrices with ordered nano-scale structure for tissue engineering. Tissue Eng 2006;12:3247-56.

26. Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006;24:227-34.

27. Célio-Mariano R, de Melo WM, Carneiro-Avelino C. Comparative radiographic evaluation of alveolar bone healing associated with autologous platelet-rich plasma after impacted mandibular third molar surgery. J Oral Maxillofac Surg 2012;70:19-24.

28. Gürbüz B, Pikkönen L, Tunali M, Urban M, Kükükocaci Z, Erkan F. Scintigraphic evaluation of osteoblastic activity in extraction sockets treated with platelet-rich fibrin. J Oral Maxillofac Surg 2010;68:980-9.

29. Mancuso JD, Bennion JW, Hull MJ. Platelet-rich plasma: A preliminary report in routine impacted mandibular third molar surgery and the prevention of alveolar osteitis. J Oral Maxillofac Surg 2003;61:40.

30. Anitua E, Prado R, Orive G. A lateral approach for sinus elevation using PRGF technology. Clin Implant Dent Relat Res 2009;11:E23-31.

31. Anitua E, Prado R, Orive G. Bilateral sinus elevation evaluating plateau rich in growth factors technology: A report of five cases. Clin Implant Dent Relat Res 2012;14:51-60.

32. Riaz R, Ravindran C, Nandakumar N, Kannadasan K, Raja KK. Lateral approach for sinus elevation using platelet rich gel. J Oral Maxillofac Surg 2010;68:980-9.
34. Schaff H, Streckbein P, Lendeckel S, Heidinger KS, Rehmann P, Boedeker RH, et al. Sinus lift augmentation using autogenous bone grafts and platelet-rich plasma: Radiographic results. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:673-8.

35. Zhang Y, Tang S, Huber CD, Lin Y, Qiu L, Rausch-Fan X. Effects of Choukroun's platelet-rich fibrin on bone regeneration in combination with deproteinized bovine bone mineral in maxillary sinus augmentation: A histological and histomorphometric study. J Craniomaxillofac Surg 2012;40:321-8.

36. Schlegel KA, Zimmermann R, Thorwarth M, Neukam FW, Klongnoi B, Nkenke E, et al. Sinus floor elevation using autogenous bone or bone substitute combined with platelet-rich plasma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:E15-25.

37. Casati MZ, de Vasconcelos Gurgel BC, Gonçalves PF, Pimentel SP, da Rocha Nogueira Filho G, Nociti FH Jr, et al. Platelet-rich plasma does not improve bone regeneration around peri-implant bone defects—A pilot study in dogs. Int J Oral Maxillofac Surg 2007;36:132-6.

38. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related osteonecrosis of the jaws–An initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011;69:2465-72.

39. Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonates related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:153-63.

40. Pautke C, Bauer F, Fischer T, Kreuzer K, Weitz J, Kesting M et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2009;67:471-6.

41. Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw: A literature review of UK policies versus international policies on the management of bisphosphonate, risk factors and prevention. Br J Oral Maxillofac Surg 2011;49:251-7.

42. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: A report of 2 cases. J Oral Implantol 2007;33:371-82.

43. Oyama T, Nishimoto S, Tsugawa T, Shimizu F. Efficacy of platelet-rich plasma in alveolar bone grafting. J Oral Maxillofac Surg 2009;67:555-8.

44. Marukawa E, Oshima H, Iino G, Morita K, Oamura K. Reduction of bone resorption by the application of platelet-rich plasma (PRP) in bone grafting of the alveolar cleft. J Maxillofac Surg 2011;39:278-83.

45. Behnia H, Khojasteh A, Soleimani M, Tehranchi A, Atashi A. Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: A preliminary report. J Craniomaxillofac Surg 2012;40:2-7.

46. Lee C, Nishihara K, Okawachi T, Iwashiwa Y, Majima H, Nakamura N. A quantitative radiological assessment of outcomes of autogenous bone graft combined with platelet-rich plasma in the alveolar cleft. Int J Oral Maxillofac Surg 2009;38:117-25.

47. Andrew P, Wroblewski BS, Meja HA, Wright VI. Application of platelet-rich plasma to enhance tissue repair. Oper Tech Orthop 2010;20:98-105.

48. Malese K, Boccone L. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C. J Cereb Blood Flow Metab 1995;15:440-9.

49. Valenzuela CF, Xiong Z, MacDonald JF, Weiner JL, Frazier CJ, Dunwiddie TV, et al. Platelet-derived growth factor induces a long-term inhibition of Nmethyl-D-aspartate receptor function. J Biol Chem 1996;271:16151-9.

50. Park SK, Solomon D, Vartanian T. Growth factor control of CNS myelination. Dev Neurosci 2001;23:327-37.

51. Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 2006;9:1371-81.

52. Elgazzar RF, Mutabagani MA, Abdelaal SE, Sadakah AA. Platelet rich plasma may enhance peripheral nerve regeneration after cyanoacrylate reanastomosis: A controlled blind study on rats. Int J Oral Maxillofac Surg 2008;37:748-55.

53. Tirassa P, Triaca V, Amendola T, Fiore M, Aloe L. EGF and NGF injected into the brain of old mice enhance BDNF and ChAT in proliferating subventricular zone. J Neurosci Res 2003;72:557-64.

54. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggs SM, et al. Increased Central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol 1995;147:53-67.

55. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.

56. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma sourced factor in the management of intravenous bisphosphonates related osteonecrosis of the jaws. J Craniomaxillofac Surg 2012;40:2-7.